Dr Songlin Xue has moved to Astellas Pharma to take up the US-based role of head of global pharmacovigilance (PV).
He will work out of the Japanese pharma company’s Northbrook, Illinois headquarters for the Americas and report to Astellas chief medical officer Sef Kurstjens.
Dr Xue has spent more than 20 years in the pharmaceutical industry, most recently at Takeda, where he was senior vice president, head global pharmacovigilance.
Prior to joining Takeda, Dr Xue held posts with a number of global pharmaceutical companies, including Novartis and Wyeth.
Astellas president and CEO Yoshihiko Hatanaka said: “I am pleased that Dr Xue will be joining us at Astellas as head of global pharmacovigilance. Dr Xue’s knowledge and experience will help the company pursue its operational excellence and further enhance our global PV and product compliance capabilities.”